PMID: 9429741Jan 16, 1998Paper

Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers

Biopharmaceutics & Drug Disposition
J J ZhaoH Cheng

Abstract

A study was conducted to (i) characterize the multiple-dose pharmacokinetics of oral montelukast sodium (MK-0476), 10 mg d-1 in healthy young subjects (N = 12), (ii) evaluate the pharmacokinetics of montelukast in healthy elderly subjects (N = 12), and (iii) compare the pharmacokinetics and oral bioavailability of montelukast between elderly and young subjects. Following oral administration of montelukast sodium, 10 mg d-1 (the therapeutic regimen for montelukast sodium) for 7 d, there was little difference in the plasma concentration-time profiles of montelukast in young subjects between day 1 and day 7 dosing. On average, trough plasma concentrations of montelukast were nearly constant, ranging from 18 to 24 ng mL-1 on days 3-7, indicating that the steady state of montelukast was attained on day 2. The mean accumulation ratio was 1.14, indicating that this dose regimen results in a 14% accumulation of montelukast. In elderly subjects, mean values of plasma clearance (Cl), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRTIV) following a 7 mg intravenous (5 min infusion) administration of montelukast sodium in the elderly were 30.8 mL min-1, 9.7 L, 6.7 h, and 5...Continue Reading

Citations

Jul 4, 2006·Indian Journal of Pediatrics·Mandeep WaliaS K Kabra
Apr 23, 2005·Pharmaceutical Research·Rohini RamakrishnanBarbara Knorr
Feb 19, 1999·Lancet·B J Lipworth
Apr 13, 2004·Journal of Pediatric Gastroenterology and Nutrition·Craig A FriesenSusan M Abdel-Rahman
Dec 17, 2004·Journal of Clinical Pharmacology·Robert L WalskyR Scott Obach
Dec 17, 2009·Therapeutics and Clinical Risk Management·James P Kemp
Aug 23, 2006·Expert Opinion on Drug Metabolism & Toxicology·Klaus Turnheim
Jul 16, 2009·Drug Metabolism Reviews·Italo PoggesiJean-Baptiste Watelet
Feb 24, 2016·Journal of Toxicology·Marwa M M RefaieAly M Abdelrahman
Jul 12, 2011·Revue des maladies respiratoires·F-X Blanc
Jul 16, 2003·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·H MechicheP Devillier
Sep 20, 2006·British Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jul 15, 2015·European Journal of Pharmacology·Eva Rahman Kabir, Nabila Morshed
Jul 4, 2006·Pulmonary Pharmacology & Therapeutics·Jürg HamacherAlbrecht Wendel
May 5, 2001·Expert Opinion on Pharmacotherapy·L García-Marcos, A Schuster
Jan 28, 2014·The Lancet. Respiratory Medicine·Kay WangAnthony Harnden
Jan 12, 2000·The Annals of Pharmacotherapy·K V Blake
Sep 25, 2017·Clinical Pharmacology and Therapeutics·Päivi HirvensaloMikko Niemi
Jan 24, 2006·Pediatric Pulmonology·Manuel Pajaron-FernandezLuis Garcia-Marcos
Aug 3, 2002·CNS Drugs·Abouch V KrymchantowskiPedro F Moreira
Nov 25, 2011·Expert Review of Clinical Pharmacology·Anna KoenenHenriette E Meyer zu Schwabedissen
Feb 4, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Anne M FilppulaJanne T Backman
Mar 13, 2002·Paediatric Drugs·Richard B R Muijsers, Stuart Noble
Dec 21, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Robert L WalskyWilliam R Proctor
Apr 3, 2007·Molecular Diagnosis & Therapy·John J Lima
Mar 3, 2021·Journal of Drug Delivery Science and Technology·Michelle Alvares SarcinelliHelvécio Vinícius Antunes Rocha
May 21, 2005·The American Journal of Geriatric Pharmacotherapy·Barry J Cusack

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.